.png){kind=icon}
.png){kind=icon}
Return
Distinct outcome patterns according to RAS and BRAF status in MSI-H/dMMR mCRC treated with immune checkpoint inhibitors: A systematic review and meta-analysis
.png){kind=icon}
PRE
AI
A
R
A
A
R
P
C
F
M
G
G
C
M
M
A
V
A
S
F
R
DOI：10.1016/j.ctrv.2026.103178.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Survival varies with RAS and BRAF mutations in MSI-H mCRC treated with ICIs. • BRAF mutation maintains poor prognosis despite similar ORR. • RAS mutation linked to modestly longer PFS. • ORR remains consistent across molecular subgroups. • Supports biomarker-based stratification in MSI-H mCRC.
Journal
IF:
10.5
Papers:
2.8K
Citations:
1.3W
Organization
No organization information available
Cited Papers